WO1999063938A3 - Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs - Google Patents

Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs Download PDF

Info

Publication number
WO1999063938A3
WO1999063938A3 PCT/US1999/012775 US9912775W WO9963938A3 WO 1999063938 A3 WO1999063938 A3 WO 1999063938A3 US 9912775 W US9912775 W US 9912775W WO 9963938 A3 WO9963938 A3 WO 9963938A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenosine
ards
administration
treatment
composition
Prior art date
Application number
PCT/US1999/012775
Other languages
French (fr)
Other versions
WO1999063938A9 (en
WO1999063938A2 (en
Inventor
Jonathan W Nyce
Jeffrey L Hill
Original Assignee
Epigenesis Pharmaceuticals Inc
Jonathan W Nyce
Jeffrey L Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/093,972 external-priority patent/US6825174B2/en
Application filed by Epigenesis Pharmaceuticals Inc, Jonathan W Nyce, Jeffrey L Hill filed Critical Epigenesis Pharmaceuticals Inc
Priority to CA002316994A priority Critical patent/CA2316994A1/en
Priority to EP99930160A priority patent/EP1011608A4/en
Priority to AU46756/99A priority patent/AU4675699A/en
Publication of WO1999063938A2 publication Critical patent/WO1999063938A2/en
Publication of WO1999063938A3 publication Critical patent/WO1999063938A3/en
Publication of WO1999063938A9 publication Critical patent/WO1999063938A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A pharmaceutical composition comprises an agent such as an adenosine A2a agonist agent and/or nucleic acid comprising an oligonucleotide(oligo) that is anti-sense to an adenosine A1, A2a, A2b or A3 receptor gene, mRNA, flanking regions or regions bridging the intro/exon borders, which oligos are effective to prevent, alleviate or inhibit adenosine-mediated cardiac, pulmonary and/or renal functional difficulties, damage or failure, such as those observed in diseases and conditions such as ARDS, hypoxia, etc. or associated with the administration of therapeutic and diagnostic agents such as adenosine cysplatin, metal ion-containing agents, etc., mixtures thereof, and optionally a surfactant, a carrier and other therapeutic and diagnostic agents and other formulation components. The composition is provided in the form of various formulations that are, for example, effective for preventing or alleviating bronchoconstriction, allergy and/or inflammation associated with ARDS, RDS, etc., deleterious side effects observed upon treatment of SVT patients, upon administration of cardiac stress tests or imaging tests, etc.
PCT/US1999/012775 1998-06-08 1999-06-08 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs WO1999063938A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002316994A CA2316994A1 (en) 1998-06-08 1999-06-08 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
EP99930160A EP1011608A4 (en) 1998-06-08 1999-06-08 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
AU46756/99A AU4675699A (en) 1998-06-08 1999-06-08 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8850198P 1998-06-08 1998-06-08
US60/088,501 1998-06-08
US8865798P 1998-06-09 1998-06-09
US09/093,972 US6825174B2 (en) 1995-06-07 1998-06-09 Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US09/093,972 1998-06-09
US60/088,657 1998-06-09

Publications (3)

Publication Number Publication Date
WO1999063938A2 WO1999063938A2 (en) 1999-12-16
WO1999063938A3 true WO1999063938A3 (en) 2000-01-27
WO1999063938A9 WO1999063938A9 (en) 2000-03-02

Family

ID=27375993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012775 WO1999063938A2 (en) 1998-06-08 1999-06-08 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs

Country Status (4)

Country Link
EP (1) EP1011608A4 (en)
AU (1) AU4675699A (en)
CA (1) CA2316994A1 (en)
WO (1) WO1999063938A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP2003535818A (en) * 2000-02-17 2003-12-02 スィーヴィー セラピューティクス インコーポレイテッド Methods of identifying and using A2B adenosine receptor antagonists that mediate mammalian cell proliferation
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
EP1434782A2 (en) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US7683037B2 (en) 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
SG155182A1 (en) 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
CN101076343A (en) 2004-10-20 2007-11-21 Cv医药有限公司 Use of A2A adenosine receptor agonists
KR101494125B1 (en) 2006-02-03 2015-02-16 길리애드 사이언시즈, 인코포레이티드 Process for preparing an a2a-adenosine receptor agonist and its polymorphs
JP2009541354A (en) * 2006-06-22 2009-11-26 シーブイ・セラピューティクス・インコーポレイテッド Use of A2A adenosine receptor agonists in the treatment of ischemia
WO2009117418A2 (en) 2008-03-17 2009-09-24 The Board Of Regents Of The University Of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040266A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for asthma
WO1998023294A1 (en) * 1996-11-26 1998-06-04 East Carolina University Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040266A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for asthma
WO1998023294A1 (en) * 1996-11-26 1998-06-04 East Carolina University Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1011608A4 *

Also Published As

Publication number Publication date
CA2316994A1 (en) 1999-12-16
EP1011608A4 (en) 2002-05-15
WO1999063938A9 (en) 2000-03-02
EP1011608A2 (en) 2000-06-28
WO1999063938A2 (en) 1999-12-16
AU4675699A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
WO1999063938A3 (en) Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
Fernández-Esparrach et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trials of spironolactone versus placebo
Messenheimer et al. Lamotrigine therapy for partial seizures: a multicenter, placebo‐controlled, double‐blind, cross‐over trial
De Oliveira et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis
Cohen et al. Colony-stimulating factor-1 plays a major role in the development of reproductive function in male mice
Plourde et al. Arimidex™: a new oral, once-a-day aromatase inhibitor
Jorizzo et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head
Gallentine et al. Levetiracetam in children with refractory status epilepticus
Kavanagh et al. Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection
Koo Current consensus and update on psoriasis therapy: a perspective from the US
JP2002515514A (en) Compositions and methods for local delivery of oligonucleotides
US20190328770A1 (en) Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
Buoni et al. Lamotrigine in typical absence epilepsy
Stein et al. Betamethasone valerate foam for treatment of nonscalp psoriasis
JP2001520196A (en) Novel use of compounds for antipruritic activity
Holtkamp et al. Erectile dysfunction with topiramate.
Page et al. A role for NK cells in greater susceptibility of young rats to metastatic formation
Burkman Jr et al. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate
Gilson et al. Metastatic Crohn’s disease: remission induced by mesalamine and prednisone
Sheffield et al. Acyclovir concentrations in human breast milk after valaciclovir administration
Dikkes et al. IGF2 knockout mice are resistant to kainic acid-induced seizures and neurodegeneration
EP0177654B1 (en) Synergistic contraceptive mixture
Bagatell et al. Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men
Moritz et al. Aldosterone secretion by the mid-gestation ovine fetus: role of the AT2 receptor
BR0001593A (en) Composition and method for the prevention and treatment of cardiopulmonary and renal disorders or deficiencies associated with commischemia, endotoxin release, ards and other drugs through the administration of certain drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA CN MX US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-66, DESCRIPTION, REPLACED BY NEW PAGES 1-64; PAGES 67-73, CLAIMS, REPLACED BY NEW PAGES 65-71; PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; PAGES 1-169, SEQUENCE LISTING, REPLACED BY NEW PAGES 1-158; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 46756/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999930160

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09509035

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999930160

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2316994

Country of ref document: CA

Ref country code: CA

Ref document number: 2316994

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1999930160

Country of ref document: EP